Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Keefe

Orthopaedic Surgery La Jolla, CA Medical Doctor

NPI 1194703348 CMS profile 710829

10710 N Torrey Pines Rd, La Jolla, CA 92037

Open in the dashboard

General payments

$30,685

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Keefe of La Jolla, CA is reported in the CMS Open Payments database as having received $30,685 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,426 18
2024 General $7,948 13
2023 General $1,125 20
2022 General $2,088 12
2021 General $8,195 9
2020 General $841 9
2019 General $64 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Keefe
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Daniel Keefe were reported at $10,426. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Daniel Keefe Orthopaedic Surgery median Middle half National median
2019 $64 $644 $140–$2,844 $163
2020 $841 $312 $75–$1,860 $114
2021 $8,195 $520 $117–$2,495 $132
2022 $2,088 $598 $128–$2,731 $149
2023 $1,125 $461 $128–$2,264 $160
2024 $7,948 $497 $134–$2,475 $164
2025 $10,426 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $26,171 33 payments
  2. DePuy Synthes Sales Inc. $1,878 27 payments
  3. ImpactOrtho, Inc. $1,225 2 payments
  4. Arthrex, Inc. $830 14 payments
  5. Stryker Corporation $257 2 payments
  6. Linvatec Corporation $188 2 payments
  7. Elevate Surgical CO $59 2 payments
  8. Smith+Nephew, Inc. $46 1 payment
  9. Bioventus LLC $17 1 payment
  10. Encore Medical, LP $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $21,934 4 payments
  2. Food and Beverage $4,011 69 payments
  3. Travel and Lodging $3,540 11 payments
  4. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. FMS Duo $6,728 2 payments
  2. INHANCE $1,495 8 payments
  3. HEALIX KNOTLESS PEEK $932 10 payments
  4. TRUESPAN $841 9 payments
  5. MILAGRO $721 7 payments
  6. RIGIDLOOP $628 7 payments
  7. TRUESPAN ORTHOCORD $566 4 payments
  8. DYNACORD $456 4 payments
  9. VAPR $311 4 payments
  10. NA $190 2 payments
  11. Other $1,358 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

154

Median for Sports Medicine: 144

Drug cost

$1,646

Median for Sports Medicine: $1,027

Branded share of claims

36.4%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 47 $733
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 56 $656
Methylprednisolone Generic 11 $135
Ondansetron Hcl Generic 27 $95
Oxycodone Hcl Generic 13 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$85,020

Of which drugs: $1,271

Medicare patients

204

Average age 72

Services billed

6,756

96 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 54%
Depression 23%
Ischemic heart disease 22%
Diabetes 18%
Atrial fibrillation 14%
Osteoporosis 14%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 81 4,720 $476
Injection, methylprednisolone acetate, 40 mg J1030 Office 25 29 $126
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 88 1,300 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record